Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

PPLPHARMA's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 0.00000
forwardPE 42.33859
debtToEquity 59.76800
earningsGrowth 0.00000
revenueGrowth -0.00900
grossMargins 0.60862
operatingMargins -0.04684
trailingEps 0.74000
forwardEps 0.00000

Piramal Pharma Limited's low earnings and revenue growth highlight potential profit shrinkage. This suggests that the company may struggle to maintain its financial performance, raising concerns about its future profitability.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

Over time, PPLPHARMA's price projections have been consistently revised lower. This suggests analysts are becoming less optimistic about the company's future prospects and are adjusting their forecasts accordingly.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


The recent buy bias for PPLPHARMA from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see PPLPHARMA as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.